Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Jon C. Ogg | Mar 5, 2013 at 11:40 AM EST

Nymox Tries for Recovery on Safety Profile of NX-1207 for Prostate Cancer

ThinkstockNymox Pharmaceutical Corp. (NASDAQ: NYMX) took a mystery beating last Friday, to the point that a single stock circuit breaker was triggered…

Paul Ausick | Mar 5, 2013 at 7:55 AM EST

J&J, Bayer Fail to Gain FDA Approval for Blood Thinner

ThinkstockThe U.S. Food and Drug Administration (FDA) last night rejected an application from Johnson & Johnson (NYSE: JNJ) and Germany’s…

Jon C. Ogg | Mar 1, 2013 at 3:06 PM EST

Pharma Merger/Buyout Hunt Continues in Biotech, Valuations Under Focus

ThinkstockThe hunt by Big Pharma stocks for smaller drug companies and biotech stocks continues. A report citing “sources” from Dow…

Jon C. Ogg | Mar 1, 2013 at 11:10 AM EST

Daily ETF Folly: Why There Is No True Biotech Representation in ETFs

Thinkstock24/7 Wall St. is taking a daily aim at the world exchange-traded funds (ETFs). Many are great, and many are…

Jon C. Ogg | Feb 28, 2013 at 12:50 PM EST

ETF Folly: Biotech ETFs, Nothing but Confusion

Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or…

Jon C. Ogg | Feb 25, 2013 at 5:08 PM EST

VIVUS Obesity Drug Sales Only About 60% of Expectations

ThinkstockVIVUS Inc. (NASDAQ: VVUS) reported a quarterly loss of $0.56 per share on Monday, but this was not an earnings…

Jon C. Ogg | Feb 25, 2013 at 11:25 AM EST

FDA Response Letter Takes over $100M from Dynavax Value

ThinkstockDynavax Technologies Corp. (NASDAQ: DVAX) was a small cap stock even before today’s news, but a complete response letter from…

Jon C. Ogg | Feb 25, 2013 at 8:15 AM EST

Deadly Dialysis Injection Recall Implodes Affymax

ThinkstockAnother big implosion is taking place in the world of biotech and biohealth. Affymax Inc. (NASDAQ: AFFY) and Takeda Pharmaceutical…

Jon C. Ogg | Feb 22, 2013 at 9:55 AM EST

Celsion Raises Much Needed Capital

ThinkstockCelsion Corp. (NASDAQ: CLSN) was one of the more recent biotech implosions we have monitored. The company’s situation looked dire, and…

Jon C. Ogg | Feb 22, 2013 at 9:15 AM EST

Biotech and Bioheath Stocks Raising Capital, Secondary Offerings

ThinkstockIt is not unusual to see biotech and biohealth companies raise cash after good news. After all, these companies either need…

Jon C. Ogg | Feb 21, 2013 at 5:20 PM EST

Europe Denies Obesity Drug Approval

ThinkstockIf you are obese in Europe, you are not about to get a little pill to take to help you change.…

Jon C. Ogg | Feb 21, 2013 at 8:15 AM EST

Repros Blasts Off After FDA Study Clearance

ThinkstockRepros Therapeutics Inc. (NASDAQ: RPRX) is surging on clinical update news this Thursday. The company’s Androxal Phase 3 program has…

Jon C. Ogg | Feb 20, 2013 at 4:27 PM EST

Ambit Biosciences Files for IPO

ThinkstockAmbit Biosciences Corp. has filed its paperwork with the Securities and Exchange Commission to come public via an initial public…

Jon C. Ogg | Feb 20, 2013 at 4:04 PM EST

Chelsea Therapeutics Back on the Map in a Serious Way

ThinkstockWhen Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) announced that the U.S. Food & Drug Administration was going to allow the…

Jon C. Ogg | Feb 20, 2013 at 9:10 AM EST

Celgene: When Biotechs Use Stock Buybacks to Juice Price and Earnings

ThinkstockWhen companies start buying back their common stock on the open market, it can have multiple outcomes. It can offset…

1 … 306 307 308 309 310 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Nymox Tries for Recovery on Safety Profile of NX-1207 for Prostate Cancer

J&J, Bayer Fail to Gain FDA Approval for Blood Thinner

Pharma Merger/Buyout Hunt Continues in Biotech, Valuations Under Focus

Daily ETF Folly: Why There Is No True Biotech Representation in ETFs

ETF Folly: Biotech ETFs, Nothing but Confusion

VIVUS Obesity Drug Sales Only About 60% of Expectations

FDA Response Letter Takes over $100M from Dynavax Value

Deadly Dialysis Injection Recall Implodes Affymax

Celsion Raises Much Needed Capital

Biotech and Bioheath Stocks Raising Capital, Secondary Offerings

Europe Denies Obesity Drug Approval

Repros Blasts Off After FDA Study Clearance

Ambit Biosciences Files for IPO

Chelsea Therapeutics Back on the Map in a Serious Way

Celgene: When Biotechs Use Stock Buybacks to Juice Price and Earnings

Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

3 Dividend Stocks Built for Retirement to Buy in June

From PC Maker to AI Giant: How Dell Rewarded Patient Investors With Nearly 1,900% Gains and AI Capex Determines The Future

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation

3 Dividend Stocks Built for Retirement to Buy in June

From PC Maker to AI Giant: How Dell Rewarded Patient Investors With Nearly 1,900% Gains and AI Capex Determines The Future

Health and Healthcare Articles

All Health and Healthcare Articles

Nymox Tries for Recovery on Safety Profile of NX-1207 for Prostate Cancer

J&J, Bayer Fail to Gain FDA Approval for Blood Thinner

Pharma Merger/Buyout Hunt Continues in Biotech, Valuations Under Focus

Daily ETF Folly: Why There Is No True Biotech Representation in ETFs

ETF Folly: Biotech ETFs, Nothing but Confusion

VIVUS Obesity Drug Sales Only About 60% of Expectations

FDA Response Letter Takes over $100M from Dynavax Value

Deadly Dialysis Injection Recall Implodes Affymax

Celsion Raises Much Needed Capital

Biotech and Bioheath Stocks Raising Capital, Secondary Offerings

Europe Denies Obesity Drug Approval

Repros Blasts Off After FDA Study Clearance

Ambit Biosciences Files for IPO

Chelsea Therapeutics Back on the Map in a Serious Way

Celgene: When Biotechs Use Stock Buybacks to Juice Price and Earnings

Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

3 Dividend Stocks Built for Retirement to Buy in June

From PC Maker to AI Giant: How Dell Rewarded Patient Investors With Nearly 1,900% Gains and AI Capex Determines The Future

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

Featured Reads

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation